Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

43results about "Non-animal cells" patented technology

A method of co-culturing helicobacter pylori and gastric mucosa epithelial cells

A method of co-culturing helicobacter pylori and gastric mucosa epithelial cells is disclosed. The method includes 1) preparing a helicobacter pylori medium; 2) adding the medium into a sterile cell culture flask and preparing a slant surface; 3) culturing gastric mucosa epithelial cells in the culture flask in which the slant surface is formed and allowing the cells to be adhered to the wall of the flask; 4) centrifuging a helicobacter pylori 48-h culture liquid, and then resuspending a centrifuging product with a cell culture liquid; and 5) adding a resuspended bacterial liquid into the culture flask in which the slant surface and the adherent cells are formed, culturing, and counting the living bacteria and observing cell morphological changes every day. A beneficial effect of the method is that the novel method of co-culturing the helicobacter pylori and the gastric mucosa epithelial cells is provided. In the novel system, the helicobacter pylori can grow normally and continuously stimulate the adherent cells to generate lesions, thus simulating a human gastric mucosa infection situation well. The problem that helicobacter pylori declines or dies and cells are not effectively stimulated because culture liquids are not suitable for growth of the helicobacter pylori in traditional methods in which helicobacter pylori are directly added is overcome.
Owner:LANZHOU UNIVERSITY

Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof

Hepatitis C virus replication at extrahepatic sites has been suggested; however, complete viral replication has only been confirmed in hepatocytes. Here we show that human adipogenic DLK-1+ stem cells (hADSC) freshly isolated from HCV-infected individuals contained viral transcripts, replication intermediates and viral antigens in vivo, and viral transcripts increased in supernatants upon prolonged ex vivo culture. Furthermore, naive hADSC isolated from HCV (−) individuals support complete replication of clinical isolates in vitro, and the infection is donor-nonspecific for cells and cross-genotypic for viruses. Viral infection/replication is mediated through CD81, LDL-R, SR-B1, EGFR, Apolipoprotein E, occludin, claudin-1, NPC1L1 and diacylglycerol acetyltransferase-1, and can be inhibited by anti-viral drugs. In addition, the physical properties of hADSC-propagated viral particles resemble clinical isolates more than JFH1/HCVcc, and viruses propagated by in vitro infected hADSC are infectious to primary human hepatocytes. Therefore, hADSC are an in vivo HCV reservoir and represent a novel venue of clinical virus-host interaction. hADSC can also be exploited as a physiologically relevant primary cell culture system to propagate clinical isolates.
Owner:FRONTIER BIO DRUG DEV LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products